Member Info for Tra1

back up now as new investors buying in

We ve been through that before, double blinded means the patient and the staff giving the Meds do not know which is Tab A or Tab B, but the staff receiving the data (SGSC in that case) are not blinded. Again when the data is presented for independent review, the assessor will be blinded.
If you remember the Telegraph article in Feb., it was a source from SGSC who commented on the INITIAL results.
Obviously the final results could be different but there is a good chance.

https://www.msn.com/en-gb/health/medical/affordable-british-made-covid-drug-could-slash-mortality-rates/ar-BB1dLH0Y?ocid=st

red market again, getting closer to the results, time to buy

you can follow them on investegate, or the company website:

https://www.investegate.co.uk/Index.aspx?searchtype=2&words=Bould+Opportunities

Both will do very well, cizzle will be a multi bagger.

it does not take long to process the data of 150 patients really, I expect much sooner results.

yes, finishing green yesterday when the the whole market was red, was a good sign.

Vaccination against influenza began in the 1930s, with large-scale availability in the United States beginning in 1945.

We still have to shut some hospital wards every winter to accommodate flu/influenza patients!

yes the PSL board still exists -:)

Presentation:

https://www.youtube.com/watch?app=desktop&v=EUfqP-9eaSM

80% discount means 500% upside potential, not counting the potential for takeover or JV and other future developments. I do expect the first day of trading will be the lowest price you will get with news flow on many milestones, (Manufacturing partner, currently in discussion, Licencing partner, CE, FDA approval, NHS collaboration). That is short/medium term.

However, if this turns to be the "biomarker of choice" for Lung Ca. similar to PSA for prostate Ca or CEA for bowel Ca; both developed to be THE mainstream tests for screening, follow up after treatment. Then, we will have a breakthrough medical discovery, sky is the limit (no hype, only scientific here), hence the multiple global patents.

p.s. Neil, since you started your journey through the medical journals, here is a little Sund. present, only a 5min read -:),

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832880/

Just shows the potential, enjoy the rest of W/E

the shareholders list (page 5,7 of the prospectus) does not give the impression that any of them is selling on admission. Most of them are Universities, charity research funds etc). AG as far as i understand is not selling anytime soon, he is not here for 20% or so, he will prbly exercise his warrants which will add cash to the company. So to a large extent the sp on admission is more or less controlled by us PIs. There are a lot of other investors waiting to buy on admission, so If we do not sell, the sp rises, simple. We waited long time, why not give it 3-6 months frame, remember iqai from 1 to 14 (yes 14x) within 6m 2019 while awaiting for certification and fda?

British Airways has not made a specific commitment to including hydrogen-powered aircraft in its fleet, but ZeroAvia claims to already have letters of intent from 15 undisclosed airlines.

Aeristech project

https://www.ainonline.com/aviation-news/aerospace/2021-05-03/case-hydrogen-powered-aircraft-gains-momentum

https://www.thetimes.co.uk/article/infrastrata-looks-for-cash-injection-for-wind-farm-bid-xdcrpkb9d

Morning,
another liquid biopsy company (Inivata), which at some point i thought it is our target, has been acquired by a big pharma, look at #ipo rns today. We have the advantage of listing with a low sp which will multibag in time, I would definitely keep cizzle and for few months.

The Group is currently in ongoing discussions with prime defence contractors regarding subcontract fabrication opportunities for a series of defence contracts, and has received several approaches from cruise operators for technical dry dockings before cruise vessels are brought back into operation.

A reminder:
Investor Webinar
Representatives from Bould’s management and Cizzle Biotechnology will be hosting an online presentation and Q&A session at 6.00 p.m. BST on Thursday 6 May 2021. This session is open to all shareholders and other interested parties.
Those who wish to attend should register via the link below and they will be provided with access details.

https://us02web.zoom.us/webinar/register/WN_J4CZWpskQFqW4IbinMSAow

is that relevant to infa?

https://www.thecourier.co.uk/fp/news/local/fife/2183875/deserted-fife-bifab-yard-welcomes-new-business/

taken from the last update= ”..... it allows it to acquire technology which has benefitted from a previous commercial engagement and subsequently technological improvement, but before final commercial terms have been reached with a licencing partner......”

reading this paragraph, i am assuming they are already in discussion with a partner? but happy to be corrected.